Germany Just Made Americans Pay for Their Healthcare Discounts

Germany just figured out a clever way to trim its healthcare budget without actually making any hard choices. They’re making us pay for it instead.

Late April brought news that German policymakers want to cap spending growth, restrict care access, and force pharmaceutical companies to hand over steep discounts. On paper, it looks like fiscal responsibility. In reality, it’s cost shifting dressed up as reform. The bill doesn’t vanish just because Berlin decided to stop paying it. Those research and development expenses still exist. When Germany and other wealthy nations suppress what they’ll pay for innovative medicines, drugmakers don’t just absorb the loss and move on. They shift those costs to the one place that still pays something close to fair value for medical innovation.

That place is us.

The numbers tell a story that should make every American furious. Our patients generate roughly three quarters of global pharmaceutical profits despite accounting for just a quarter of worldwide GDP. We’re bankrolling the world’s drug development while patients in Paris and Berlin and London pay bargain basement prices for the exact same treatments. It’s the most lopsided arrangement imaginable, and it’s been going on for decades.

President Trump spent months trying to fix this freeloading problem. He pressed other countries to pay fair value for new treatments instead of letting American patients carry the load. The approach makes sense because there’s really no alternative that doesn’t end in disaster. If we copied Europe’s price control tactics, which Democrats have suggested repeatedly, companies would lose the ability to earn returns on new research. Global development of life saving drugs would slow to a crawl or stop entirely. You can’t fund tomorrow’s cures with yesterday’s revenue.

So the only workable path forward involves making wealthy allies pay their share. Trump actually made progress on this front. In April, he convinced the United Kingdom to increase its spending on new medicines. The deal proved that firm negotiation could yield real results when Washington decided to stop accepting the status quo.

But Germany is testing our resolve right now. They already spend far less than the United States on medicines even after you account for their smaller population and economy. This new plan will deepen that gap by imposing strict limits on health spending growth and extracting money directly from manufacturers to fund drug coverage. Soon Germany will pay even less than it already does for innovative treatments.

The result? Higher costs concentrated in the American market or reduced investment in new cures. Possibly both. Either way, American patients shoulder the burden while German patients benefit from our willingness to fund research they won’t pay for.

And here’s the thing that really matters. If Washington fails to respond to Germany’s move, the broader effort to end foreign freeloading loses all credibility. Other countries will watch and learn. They’ll assume they can continue riding free without facing any real consequences. The UK deal becomes an anomaly instead of a precedent.

We need to make a stand, and fortunately the Trump administration has genuine negotiating leverage. The recent UK agreement shows that U.S. trade officials have plenty of tools to obtain cooperation from foreign governments when they decide to use them. Those tools should come out now. We should push for fair pricing, knock down barriers that limit market access, and make absolutely clear that continued freeloading comes with costs.

Germany isn’t some struggling economy that needs our charity. They’re a wealthy nation making a calculated choice to suppress prices and let Americans pick up the slack. That’s not partnership. That’s exploitation. And it needs to stop before every other country in Europe decides to follow the same playbook.

Related: Failed Immigration Policy Leaves Two New York Women Stabbed to Death